NCT06377930CompletedPhase 2
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
A Phase 2A, Multicenter, Open-label Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 17 Apr 2024
- Start date
- 10 Oct 2024
- Primary completion date
- 26 Sept 2025
- Lead sponsor
- Rapport Therapeutics Inc.
- Diseases
- Epilepsy
- NCT number
- NCT06377930
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 30
- From 10 Oct 2024 to the primary completion date, 26 Sept 2025
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who have had epilepsy surgery within the last 12 months before screening
Other illness
- Participants with generalized onset seizures in the past 10 years
- History of status epilepticus while on antiseizure medications within 2 years of screening
Other
- Individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods
Who the study is looking for
- Medically refractory focal epilepsy with an implanted responsive neurostimulator device placed correctly in a seizure onset zone that meet several device-related criteria and demonstrated history of compliance with interrogation of the RNS device and upload of data
- If currently treated with antiseizure medications, up to a maximum of 4 concomitant mediations are allowed
- At least 1 clinical seizure during the 8-week retrospective eligibility period
- Participants in otherwise good health as determined by the investigator
- Willing and able to adhere to all aspects of the protocol
- A demonstrated history of compliance with interrogation of the RNS device and upload of data before screening
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Consultants in Epilepsy and Neurology PLLC Coordinator of this site? Confirm its status | Boise | United States | Unknown status |
| Cleveland Clinic Foundation Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
| Baylor College of Medicine Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| University of Texas Health Science Center, Houston Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| IU Health Neuroscience Center, Goodman Hall Coordinator of this site? Confirm its status | Indianapolis | United States | Unknown status |
| The University of Kansas Medical Center Epilepsy Clinic Coordinator of this site? Confirm its status | Kansas City | United States | Unknown status |
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
| Yale University Coordinator of this site? Confirm its status | New Haven | United States | Unknown status |
| NYU Langone Comprehensive Epilepsy Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| University of Pennsylvania - Department of Neurology Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| Thomas Jefferson University Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.